What is Biktarvy used to treat?
Biktarvy is an HIV treatment. It’s used as a complete regimen to treat HIV-1 infection in adults and adolescents who weigh at least 35 kg, and in some cases for people with HIV who have no known resistance to its components (bictegravir, emtricitabine, and tenofovir alafenamide) [1].
How does Biktarvy work in HIV?
Biktarvy combines three medicines with different HIV targets, suppressing the virus:
- Bictegravir blocks HIV integrase, which the virus needs to copy into the host cell.
- Emtricitabine and tenofovir alafenamide are both nucleoside/nucleotide reverse transcriptase inhibitors, which block HIV replication after infection [1].
Is Biktarvy used for prevention (like PrEP)?
Biktarvy is not used as pre-exposure prophylaxis (PrEP) to prevent HIV. It’s prescribed to treat people who already have HIV infection [1].
What dosing situations affect who can use it?
Use depends on factors like prior resistance to the drug components and current medication needs. The product labeling and prescriber guidance specify eligibility based on resistance testing and clinical context [1].
What are common alternatives people compare it with?
People often compare Biktarvy with other once-daily single-tablet HIV regimens (different drug combinations) when choosing a first-line or switch therapy. Coverage and suitability can vary based on resistance, kidney function, drug interactions, and individual response [1].
Sources
[1] https://www.drugs.com/biktarvy.html